CRMD NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

CorMedix Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 7.53 USD
-4.3% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -0.9% below the Trend Line and sits at 15.9% of its 52-week range. The latest completed week returned -4.3%, after a -13.9% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers. Options positioning is bullish with 41/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 25 out of 100
Latest Close 7.53 USD 31 Jul 2026
1W Return -4.3% latest completed week
4W Return -13.9% short-term follow-through
12W Return -4.9% quarterly tape
Trend Breadth 21.2% 11 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.3% Latest completed week; four-week move -13.9%. Indicator stack 19/50 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 41/100 conviction; expected move 15.6%. News sentiment 53/100 65 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -0.9% below the Trend Line and sits at 15.9% of its 52-week range. The latest completed week returned -4.3%, after a -13.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2412-week average 0.20

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.24Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -13.9% over four weeks, -4.9% over 12 weeks, and -35.3% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W-4.3%
4W-13.9%
12W-4.9%
26W-3.0%
52W-35.3%
Active trend streak2 weeks
Active weeks in one year11
Trend breadth21.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.30Latest activity-pressure read.
Pressure change-71.2%Four-week change in activity pressure.
Leadership-26.39Latest relative-leadership reading.
RS change-25.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength89/100Blend of value, momentum, and quality. Underlying universe rank 12; rank 1 is best.
Value95/100Relative valuation strength. Underlying universe rank 6; rank 1 is best.
Quality98/100Profitability and accounting quality. Underlying universe rank 3; rank 1 is best.
Momentum11/100Medium-term price momentum. Underlying universe rank 90; rank 1 is best.
Growth99/100Revenue and earnings growth. Underlying universe rank 2; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
3.4x
Price divided by trailing earnings.
Price / sales
1.5x
Market value relative to trailing revenue.
EV / EBITDA
2.8x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
33.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
85.8%
Gross profit retained from each unit of revenue.
Operating margin
46.9%
Operating profit retained from revenue.
Free-cash-flow margin
49.7%
Free cash flow generated from revenue.
Return on invested capital
45.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
384.6%
Latest one-year revenue growth.
EPS growth
953.6%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-13.5%
Net share repurchases relative to market value.
Shareholder yield
-13.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

CRMD shows bullish options pressure with a 41/100 conviction score, put-call volume ratio of 0.38, expected move of 15.6%, and Sharemaestro trend signal active.

Conviction41/100
Expected move15.6%
Put/call volume0.38
Pressure51
Speculation9
Volatility86
Trend agreement33
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 65 relevant articles.

14 positive · 45 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move15.6%Nearest-chain priced movement where available.
52-week drawdown-49.7%Distance below the 52-week high.
13-week volatility5.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+11.5%Week of 3 Jul.
Worst week-9.5%Week of 26 Jun.
Latest week-4.3%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains6
Flat weeks0
Modest losses6
Sharp losses7
Recent vol5.6%13-week weekly-return volatility.
Base vol8.9%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew5.5% / -7.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape27/100

Trend, activity pressure, participation, and risk combine to a 27/100 tape read.

 Indicator analysis38/100

Latest 12-week confirmation: trend 2/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.24; No reversal markers Factors75/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 88; Small Cap Core rank 14 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options51/100

CRMD shows bullish options pressure with a 41/100 conviction score, put-call volume ratio of 0.38, expected move of 15.6%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 15.6% Sentiment53/100

Weighted news tone is neutral across 65 relevant articles.

CorMedix (CRMD) Projected to Announce Quarterly Earnings on Thursday Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20267.53 USD-4.3%7.60 USD7.72 USD0.30-26.395.6MOn
24 Jul 20267.87 USD-6.5%7.75 USD7.70 USD0.58-23.654.4MOn
17 Jul 20268.42 USD0.2%7.91 USD7.68 USD0.82-20.523.9MOff
10 Jul 20268.40 USD-4.0%8.03 USD7.65 USD0.94-24.704.5MOff
3 Jul 20268.75 USD11.5%8.13 USD7.62 USD1.03-21.005.0MOff
26 Jun 20267.85 USD-9.5%8.19 USD7.59 USD0.97-29.2812.2MOff
19 Jun 20268.67 USD-0.8%8.25 USD7.56 USD0.91-26.476.0MOff
12 Jun 20268.74 USD4.5%8.29 USD7.54 USD0.85-25.186.7MOff
5 Jun 20268.36 USD-0.9%8.37 USD7.52 USD0.79-28.115.3MOff
29 May 20268.44 USD5.8%8.45 USD7.50 USD0.72-31.854.7MOff
22 May 20267.98 USD5.7%8.54 USD7.48 USD0.65-34.617.4MOff
15 May 20267.55 USD-4.7%8.65 USD7.46 USD0.54-38.3010.6MOff
8 May 20267.92 USD1.7%8.73 USD7.44 USD0.40-36.414.9MOff
1 May 20267.79 USD5.0%8.83 USD7.43 USD0.10-34.935.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.